Étiquette : neuroimagerie

The Impact of Cannabidiol on Human Brain Function : A Systematic Review, Albert Batalla et al., 2021

The Impact of Cannabidiol on Human Brain Function : A Systematic Review Albert Batalla, Julian Bos, Amber Postma and Matthijs G. Bossong Frontiers in Pharmacology, January 2021 | Volume 11 | Article 618184, 1-15. doi : 10.3389/fphar.2020.618184   Background : Accumulating evidence suggests that the non-intoxicating cannabinoid compound cannabidiol (CBD) may have antipsychotic and anxiolytic properties, and thus may be a promising new agent in the treatment of psychotic and anxiety disorders. However, the neurobiological substrates underlying the potential therapeutic effects of CBD are still unclear. The aim of this systematic review is to provide a detailed and up-todate systematic literature overview of neuroimaging studies [...]

Lire la suite

Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans, Paul Cumming et al., 2021

Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans Paul Cumming, Milan Scheidegger, Dario Dornbierer, Mikael Palner, Boris B. Quednow and Chantal Martin-Soelch Molecules, 2021, 26, 2451 doi : 10.3390/molecules26092451   Abstract : Hallucinogens are a loosely defined group of compounds including LSD, N,Ndimethyltryptamines, mescaline, psilocybin/psilocin, and 2,5-dimethoxy-4-methamphetamine (DOM), which can evoke intense visual and emotional experiences. We are witnessing a renaissance of research interest in hallucinogens, driven by increasing awareness of their psychotherapeutic potential. As such, we now present a narrative review of the literature on hallucinogen binding in vitro and ex vivo, and the various molecular imaging studies with positron [...]

Lire la suite

Association of Cannabis Use During Adolescence With Neurodevelopment, Matthew D. Albaugh et al., 2021

Association of Cannabis Use During Adolescence With Neurodevelopment Matthew D. Albaugh, PhD; Jonatan Ottino-Gonzalez, PhD; Amanda Sidwell, BS; Claude Lepage, PhD; Anthony Juliano, PsyD; Max M. Owens, PhD; Bader Chaarani, PhD; Philip Spechler, PhD; Nicholas Fontaine, BS; Pierre Rioux, MSc; Lindsay Lewis, PhD; Seun Jeon, PhD; Alan Evans, PhD; Deepak D’Souza, MD; Rajiv Radhakrishnan, MD; Tobias Banaschewski, MD, PhD; Arun L.W. Bokde, PhD; Erin Burke Quinlan, PhD; Patricia Conrod, PhD; Sylvane Desrivières, PhD; Herta Flor, PhD; Antoine Grigis, PhD; Penny Gowland, PhD; Andreas Heinz, MD, PhD; Bernd Ittermann, PhD; Jean-Luc Martinot,MD, PhD; Marie-Laure Paillère Martinot,MD, PhD; Frauke Nees, PhD; Dimitri Papadopoulos [...]

Lire la suite

Psilocybin for treatment-resistant depression : fMRI-measured brain mechanisms, Robin L. Carhart-Harris et al., 2017

Psilocybin for treatment-resistant depression : fMRI-measured brain mechanisms Robin L Carhart-Harris, Leor Roseman, Mark Bolstridge, Lysia Demetriou, J Nienke Pannekoek, Matthew B Wall, Mark Tanner, Mendel Kaelen, John McGonigle, Kevin Murphy, Robert Leech, H Valerie Curran & David J Nutt Nature, Scientific Reports, 2017, 7, 13187 |1-11 Doi : 10.1038/s41598-017-13282-7   Abstract Psilocybin with psychological support is showing promise as a treatment model in psychiatry but its therapeutic mechanisms are poorly understood. Here, cerebral blood flow (CBF) and blood oxygen-level dependent (BOLD) resting-state functional connectivity (RSFC) were measured with functional magnetic resonance imaging (fMRI) before and after treatment with psilocybin (serotonin agonist) for treatment-resistant depression (TRD). [...]

Lire la suite

Neural Mechanisms for the Cannabinoid Modulation of Cognition and Affect in Man : A Critical Review of Neuroimaging Studies, Sagnik Bhattacharyya et al., 2012,

Neural Mechanisms for the Cannabinoid Modulation of Cognition and Affect in Man : A Critical Review of Neuroimaging Studies Sagnik Bhattacharyya, Zerrin Atakan, Rocio Martin-Santos, Jose A. Crippa and Philip K. McGuire Current Pharmaceutical Design, 2012, 18, 5045-5054   Abstract Pharmacological challenge in conjunction with neuroimaging techniques has been employed for over two decades now to understand the neural basis of the cognitive, emotional and symptomatic effects of the main ingredients of cannabis, the most widely used illicit drug in the world. This selective critical review focuses on the human neuroimaging studies investigating the effects of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), the two main cannabinoids [...]

Lire la suite

LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation, Rainer Kraehenmann et al., 2017

LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation Rainer Kraehenmann, Dan Pokorny, Helena Aicher, Katrin H. Preller, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz and Franz X. Vollenweider Frontiers in Pharmacology, 2017, Volume 8, Article 814, 1-9. Doi : 10.3389/fphar.2017.00814   Rationale : Stimulation of serotonin 2A (5-HT2A) receptors by lysergic acid diethylamide (LSD) and related compounds such as psilocybin has previously been shown to increase primary process thinking – an ontologically and evolutionary early, implicit, associative, and automatic mode of thinking which is typically occurring during altered states of consciousness such as dreaming. However, it is still largely unknown whether LSD induces [...]

Lire la suite

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers, Rainer Kraehenmann et al., 2014

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers Rainer Kraehenmann, Katrin H. Preller, Milan Scheidegger, Thomas Pokorny, Oliver G. Bosch, Erich Seifritz, and Franz X. Vollenweider Biological Psychiatry, 2014. http://dx.doi.org/10.1016/j.biopsych.2014.04.010   Background : The amygdala is a key structure in serotonergic emotion-processing circuits. In healthy volunteers, acute administration of the serotonin 1A/2A/2C receptor agonist psilocybin reduces neural responses to negative stimuli and induces mood changes toward positive states. However, it is little known whether psilocybin reduces amygdala reactivity to negative stimuli and whether any change in amygdala reactivity is related to mood change. Methods : This study assessed the effects of [...]

Lire la suite

Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users, Camilla Beale et al., 2018

Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users Camilla Beale, Samantha J. Broyd, Yann Chye, Chao Suo, Mark Schira, Peter Galettis, Jennifer H. Martin, Murat Yücel and Nadia Solowij Cannabis and Cannabinoid Research, 2018, 3, 1, 94-107. Doi : 10.1089/can.2017.0047 Abstract Introduction : Chronic cannabis use is associated with neuroanatomical alterations in the hippocampus. While adverse impacts of cannabis use are generally attributed to D9 tetrahydro-cannabinol, emerging naturalistic evidence suggests cannabidiol (CBD) is neuroprotective and may ameliorate brain harms associated with cannabis use, including protection from hippocampal volume loss. This study examined whether prolonged administration of CBD to regular cannabis users [...]

Lire la suite

Cannabis Use in Adolescence : A Review of Neuroimaging Findings, Yann Chye et al., 2019

Cannabis Use in Adolescence : A Review of Neuroimaging Findings Yann Chye, Erynn Christensen & Murat Yücel Journal of Dual Diagnosis, 2019 Doi : 10.1080/15504263.2019.1636171   ABSTRACT Objective : Shifting policies and widespread acceptance of cannabis for medical and/or recreational purposes have fueled worries of increased cannabis initiation and use in adolescents. In particular, the adolescent period is thought to be associated with an increased susceptibility to the potential harms of repeated cannabis use, due to being a critical period for neuromaturational events in the brain. This review investigates the neuroimaging evidence of brain harms attributable to adolescent cannabis use. Methods : PubMed and Scopus searches were [...]

Lire la suite

Neuroanatomical alterations in people with high and low cannabis dependence, Valentina Lorenzetti et al., 2019

Neuroanatomical alterations in people with high and low cannabis dependence Valentina Lorenzetti, Yann Chye, Chao Suo, Mark Walterfang, Dan I Lubman, Michael Takagi, Sarah Whittle, Antonio Verdejo-Garcia, Janna Cousijn, Christos Pantelis, Marc Seal, Alex Fornito, Murat Yücel and Nadia Solowij Australian & New Zealand Journal of Psychiatry, 2019, 1–8 https://doi.org/10.1177/0004867419859077   Abstract Objectives : We aimed to investigate whether severity of cannabis dependence is associated with the neuroanatomy of key brain regions of the stress and reward brain circuits. Methods : To examine dependence-specific regional brain alterations, we compared the volumes of regions relevant to reward and stress, between high-dependence cannabis users (CD+, n = 25), low [...]

Lire la suite